Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand

Journal of Immunology

Volumn 184, Issue 7, 2010, Pages 3394-3400

  Higham, Eileen M ^a,b   Dane Wittrup, K ^a,b   Chen, Jianzhu ^b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; CANCER VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; INTERFERON PRODUCTION; LYMPH NODE; LYMPHOCYTE TRANSFER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR IMMUNOLOGY; ANIMAL; BIOSYNTHESIS; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; TRANSGENIC MOUSE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; IMMUNE TOLERANCE; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL;

EID: 77951639701     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903111     Document Type: Article

References (45)

1. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
2. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
3. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
4. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
5. Chomarat, P., J. Banchereau, J. Davoust, and A. K. Palucka. 2000. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1: 510-514.
6. Curiel, T. J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567.
7. Gabrilovich, D., T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, and D. P. Carbone. 1998. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92: 4150-4166. (Pubitemid 28544331)
8. Menetrier-Caux, C., G. Montmain, M. C. Dieu, C. Bain, M. C. Favrot, C. Caux, and J. Y. Blay. 1998. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791. (Pubitemid 29005881)
9. Kaliński, P., J. H. Schuitemaker, C. M. Hilkens, and M. L. Kapsenberg. 1998. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161: 2804-2809. (Pubitemid 28425700)
10. O'Neill, D. W., S. Adams, and N. Bhardwaj. 2004. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104: 2235-2246. (Pubitemid 39331818)
11. van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukoc. Biol. 67: 2-17.
12. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480. (Pubitemid 28292195)
13. Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478. (Pubitemid 28292194)
14. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483. (Pubitemid 28292196)
15. French, R. R., H. T. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5: 548-553.
16. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5: 774-779.
17. Sotomayor, E. M., I. Borrello, E. Tubb, F. M. Rattis, H. Bien, Z. Lu, S. Fein, S. Schoenberger, and H. I. Levitsky. 1999. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5: 780-787.
18. Mauri, C., L. T. Mars, and M. Londei. 2000. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat. Med. 6: 673-679.
19. Kedl, R. M.,M. Jordan, T. Potter, J. Kappler, P.Marrack, and S. Dow. 2001. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc. Natl. Acad. Sci. U.S.A. 98: 10811-10816.
20. McGregor, C. M., S. P. Schoenberger, and E. A. Green. 2004. CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes. Proc. Natl. Acad. Sci. U.S.A. 101: 9345-9350.
21. Bartholdy, C., S. O. Kauffmann, J. P. Christensen, and A. R. Thomsen. 2007. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J. Immunol. 178: 1662-1670. (Pubitemid 46154638)
22. Hussein, M. A., J. R. Berenson, R. Niesvizky, N. C. Munshi, K. L. Harrop, M. McDonald, and J. G. Drachman. 2005. A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood 107: 106-110.
23. Forero-Torres, A., R. R. Furman, J. D. Rosenblatt, A. Younes, K. Harrop, J. G. Drachman, and R. Advani. 2006. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. J. Clin. Oncol. 24: 7534 (Abstr.).
24. Bensinger, W., S. Jagannath, P. S. Becker, K. C. Anderson, E. A. Stadtmauer, L. Aukerman, J. Fox, S. Girish, S. Bilic, S. Guzy, et al. 2006. A phase 1 dose escalation study of a fully human, antagonistic anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. Blood 108: 3575 (Abstr.).
25. Byrd, J. C., I. W. Flinn, K. D. Khan, T. J. Kipps, L. Aukerman, J. Fox, S. Girish, S. Guzy, S. Bilic, A. Solinger, et al. 2006. Pharmacokinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonistic anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 108: 2837 (Abstr.).
26. Vonderheide, R. H., K. T. Flaherty, M. Khalil, M. S. Stumacher, D. L. Bajor, N. A. Hutnick, P. Sullivan, J. J. Mahany, M. Gallagher, A. Kramer, et al. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25: 876-883.
27. Vonderheide, R. H., J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, et al. 2001. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19: 3280-3287.
28. Wierda, W. G., M. J. Cantwell, S. J. Woods, L. Z. Rassenti, C. E. Prussak, and T. J. Kipps. 2000. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917-2924.
29. Rousseau, R. F., E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, et al. 2006. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107: 1332-1341.
30. Vonderheide, R. H. 2007. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 13: 1083-1088.
31. Early, G. S., W. Zhao, and C. M. Burns. 1996. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 157: 3159-3164.
32. Kitagawa, M., H. Suzuki, Y. Adachi, H. Nakamura, S. Yoshino, and T. Sumida. 2001. Interferon-gamma enhances interleukin 12 production in rheumatoid synovial cells via CD40-CD154 dependent and independent pathways. J. Rheumatol. 28: 1764-1771. (Pubitemid 32726921)
33. Balasa, B., T. Krahl, G. Patstone, J. Lee, R. Tisch, H. O. McDevitt, and N. Sarvetnick. 1997. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 159: 4620-4627. (Pubitemid 127470625)
34. Gerritse, K., J. D. Laman, R. J. Noelle, A. Aruffo, J. A. Ledbetter, W. J. Boersma, and E. Claassen. 1996. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 93: 2499-2504.
35. Tan, J., T. Town, Z. Suo, Y. Wu, S. Song, A. Kundtz, J. Kroeger, J. Humphrey, F. Crawford, and M. Mullan. 1999. Induction of CD40 on human endothelial cells by Alzheimer's beta-amyloid peptides. Brain Res. Bull. 50: 143-148.
36. Larsen, C. P., D. Z. Alexander, D. Hollenbaugh, E. T. Elwood, S. C. Ritchie, A. Aruffo, R. Hendrix, and T. C. Pearson. 1996. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 61: 4-9.
37. Kirk, A. D., L. C. Burkly, D. S. Batty, R. E. Baumgartner, J. D. Berning, K. Buchanan, J. H. Fechner, Jr., R. L. Germond, R. L. Kampen, N. B. Patterson, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5: 686-693.
38. Geldart, T., and T. Illidge. 2005. Anti-CD 40 monoclonal antibody. Leuk. Lymphoma 46: 1105-1113.
39. Bai, A., E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen. 2008. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Natl. Acad. Sci. U.S.A. 105: 13003-13008.
40. Shen, C. H., Q. Ge, O. Talay, H. N. Eisen, A. García-Sastre, and J. Chen. 2008. Loss of IL-7R and IL-15R expression is associated with disappearance of memory T cells in respiratory tract following influenza infection. J. Immunol. 180: 171-178.
41. Rolink, A., F. Melchers, and J. Andersson. 1996. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 5: 319-330. (Pubitemid 26366755)
42. Kornbluth, R. S., K. Kee, and D. D. Richman. 1998. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc. Natl. Acad. Sci. U.S.A. 95: 5205-5210.
43. Yellin, M. J., K. Sippel, G. Inghirami, L. R. Covey, J. J. Lee, J. Sinning, E. A. Clark, L. Chess, and S. Lederman. 1994. CD40 molecules induce downmodulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J. Immunol. 152: 598-608.
44. Zhou, J., X. Shen, J. Huang, R. J. Hodes, S. A. Rosenberg, and P. F. Robbins. 2005. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175: 7046-7052. (Pubitemid 41598952)
45. Klebanoff, C. A., L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A. R. Cardones, S. E. Finkelstein, D. C. Palmer, P. A. Antony, S. T. Hwang, S. A. Rosenberg, et al. 2005. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U.S.A. 102: 9571-9576.